Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Mol Med ; 14(3): 349-60, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24236455

ABSTRACT

Bone marrow stromal cell antigen 2 (BST-2, also known as tetherin, CD317, or HM1.24) has recently been identified as a host restriction factor against diverse families of enveloped viruses. However, the effects of BST-2 on the life cycle of hepatitis C virus (HCV), an enveloped RNA virus, remain unclear and controversial. Here we demonstrated that human hepatocytes including Huh7.5.1 cells, primary human hepatocytes (PHHs), and HepG2 cells constitutively expressed low to moderate levels of endogenous BST-2 on the cell surface, which could be robustly up-regulated by all three types of interferons (IFNs) such as IFN-α, IFN-γ, and IFN-λ. IFN-α and IFN-γ showed a synergistic effect in induction of BST-2 expression on human hepatocytes. Over-expression of BST-2 by BST-2-expressing vector transfection or up-regulation of BST-2 by IFN stimulation markedly suppressed HCV production, whereas shRNA-mediated depletion of endogenous BST-2 significantly enhanced HCV production in infected Huh7.5.1 cells. IFN-mediated anti-HCV activity was partially but significantly diminished by shRNA-mediated knockdown of BST-2 expression, indicating that BST- 2 upregulation is directly involved in IFN-mediated inhibition of HCV production. We also found that both BST-2 and HCV core co-localized with intracellular lipid droplets (LDs), suggesting that BST-2-HCV interaction may take place around LDs as LDs constitute an important intracellular organelle for HCV assembly and replication. Taken together, our data suggest that BST-2 is a host restriction factor against HCV, and induction of BST-2 in hepatocytes could be one of the mechanisms by which current HCV standard therapy (IFN-α plus ribavirin) achieves a sustained virological response (SVR).


Subject(s)
Antigens, CD/metabolism , Hepacivirus/pathogenicity , Hepatocytes/drug effects , Hepatocytes/metabolism , Interferons/pharmacology , Antigens, CD/genetics , Cell Line, Tumor , Cells, Cultured , GPI-Linked Proteins/genetics , GPI-Linked Proteins/metabolism , Hep G2 Cells , Humans , Interferon-alpha/pharmacology , Interferon-gamma/pharmacology , RNA, Small Interfering , Virus Replication/drug effects
2.
CAP Today ; 15(1): 6, 8, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11317558
3.
Int J Mol Med ; 3(2): 153-5, 1999 Feb.
Article in English | MEDLINE | ID: mdl-9917522

ABSTRACT

Based on positive identification of DNA replication and mitotic division in cardiomyocytes isolated from failing hearts, it has been proposed that adult ventricular cardiomyocytes can gain the capacity to proliferate with progression of heart failure. However, due to the lack of a reliable method to distinctly image individual cardiac cells within the myocardial syntitium, such a concept still remains largely controversial. In the present study, we used laser confocal microscopy, to image cross-sections of intact myocardium stained with fluorescein-conjugated wheat germ agglutinin and propidium iodide. This approach allowed to clearly separate the profile of individual myocytes within cardiac tissue sections. We found that in the left ventricles of dogs, subjected to tachycardia-induced cardiomyopathy, the number of cells was significantly increased in both longitudinal and transversal sections. Treatment with the angiotensin-converting enzyme inhibitor, enalapril, reversed these changes to values similar to those found in controls. Therefore, this study provides evidence, at the in situ level, for cellular hyperplasia in heart failure. This supports the more general notion that adult cardiomyocytes may not be terminally differentiated, and that an increase in cell number could contribute to the increase in left ventricular mass observed with progression of disease.


Subject(s)
Cardiomyopathies/etiology , Myocardium/pathology , Tachycardia/complications , Animals , Cardiomyopathies/pathology , Disease Models, Animal , Dogs , Hypertrophy, Left Ventricular/etiology , Hypertrophy, Left Ventricular/pathology , Tachycardia/pathology , Ventricular Remodeling
SELECTION OF CITATIONS
SEARCH DETAIL
...